BioVie trial data suggest bezisterim improves cognition in high-inflammation Long COVID subgroup
BIVI•BioVie reported exploratory Phase 2 trial analyses linking high inflammation to cognitive improvements with bezisterim in Long COVID, but the 203-participant study found no statistically significant efficacy improvements overall after 12 weeks.
1. Trial findings
BioVie presented Phase 2 ADDRESS-LC findings at the RECOVER-TLC workshop on November 4-5, 2026. Exploratory analyses linked high inflammation to cognitive improvements, while patients with low myeloid cell levels showed improvements in fatigue and post-exertional malaise. Safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group. Additional data are scheduled for presentation at the Long COVID International Conference in Nice, France, on November 12-13, 2026.
